One of the hallmarks of malignancy is the polarization of tumor-associated macrophages (TAMs) from a pro-immune (M1-like) phenotype to an immune-suppressive (M2-like) phenotype. However, the molecular basis of the process is still unclear. MicroRNA (miRNA) comprises a group of small, non-coding RNAs that are broadly expressed by a variety of organisms and are involved in cell behaviors such as suppression or promotion of tumorigenesis. Here, we demonstrate that miR-19a-3p, broadly conserved among vertebrates, was downregulated in RAW264.7 macrophage cells of the M2 phenotype in conditoned medium of 4T1 mouse breast tumor cells. This downregulation correlated with an increased expression of the Fra-1 gene, which was reported to act as a prooncogene by supporting the invasion and progression of breast tumors. We found significant upregulation of miR-19a-3p in RAW264.7 macrophages after transfection with a miR-19a-3p mimic that resulted in a significant suppression of the expression of this gene. In addition, we could measure the activity of binding between miR-19a-3p and Fra-1 with a psiCHECK luciferase reporter system. Further, transfection of RAW264.7 macrophage cells with the miR-19a-3p mimic decreased the expression of the Fra-1 downstream genes VEGF, STAT3 and pSTAT3. Most importantly, the capacity of 4T1 breast tumor cells to migrate and invade was impaired in vivo by the intratumoral injection of miR-19a-3p. Taken together, these findings indicate that miR-19a-3p is capable of downregulating the M2 phenotype in M2 macrophages and that the low expression of this miRNA has an important role in the upregulation of Fra-1 expression and induction of M2 macrophage polarization.
INTRODUCTION
MicroRNAs (miRNAs) comprise a family of B22-nucleotide-long RNA molecules. They are transcribed from various genetic regions and processed in the nuclei through the cytoplasm, becoming mature single-stranded miRNA molecules. It is well recognized that miRNAs regulate gene expression in eukaryotic cells. [1] [2] [3] They are expressed in various species and are involved in cellular processes by targeting the 3 0 untranslated regions (UTRs) of target mRNAs. MiRNAs function as negative regulators of gene expression by increasing mRNA decay or by blocking the process of translation. Altered expression of the miRNA species is well established in human cancer cells, [4] [5] [6] which are involved in tumor development, progression and metastasis by targeting mRNAs of oncogenes or tumor suppressor genes. Moreover, the different types of cancer cells have revealed distinct miRNA expression profiles, indicating that analysis of miRNA expression patterns could aid in identifying miRNAs that regulate tumor progression. [7] [8] [9] [10] Although miRNAs are becoming increasingly established as regulatory molecules in cancers, the roles of miRNA expression in tumor development and as potential markers for diagnosis, prognosis and pharmacogenomics remain to be established.
Tumor-associated macrophages(TAMs) coexist in tumors and function as an accomplice to promote tumor progression and metastasis, especially once programed and polarized into a proangiogenic/immune-suppressive(M2-like) phenotype by the tumor microenvironment (TME). 11 There is increasing evidence to show that TAMs accumulate mainly in the vascular, necrotic/ hypoxic areas of tumors, where they presumably act to clean necrotic cell debris from their sites. 12 TAMs located in these sites of solid tumor respond to the hypoxia present with altered gene expression, leading to the development of a distinct pro-tumor phenotype. In this case, TAMs provide an ideal therapeutic target for blocking tumor progression and invasion after being re-programed and polarized to express a pro-immune (M1-like) phenotype. [13] [14] [15] Fos-related antigen-1 (Fra-1) belongs to the AP1 family, which is overexpressed by many human and mouse epithelial tumor cells and is associated with metastasis to lymph nodes. 16 Actually, Fra-1 has been considered to have prognostic significance, particularly for human esophageal squamous cell carcinoma, and to be a regulator of the malignant phenotype of glioma cells. 17 , 18 We previously reported that Fra-1 has a key role in the polarization of TAMs from the M1 to the M2 phenotype. In other words, expression of Fra-1 could be upregulated in TAMs that responded to stimulation by TME, leading to an increased proportion of M2-like TAMs. 19, 20 Recently, it was reported that Fra-1 is indeed a miRNA target that may control tumor invasion and migration.
Here, we identified the microRNA expression pattern in TAMs induced by stimuli from the TME in a mouse breast tumor model. Further, our study demonstrated an important normal mechanism by which miRNAs could induce the phenotype switch between TAMs and normal macrophages by regulating the expression of the Fra-1 gene and the Fra-1/STAT3 signaling pathway. Together, these findings aided us in exploring the potential of therapy targets on miRNA capable of regulating the switching of the TAM phenotype, resulting in remodeling of the TME.
RESULTS
Tumor microenvironment changes miRNA expression patterns and enhances the expression of Fra-1 in TAMs A search for potential miRNAs that target the 3 0 UTR of Fra-1 was based on the miRBase and TargetScan software prediction. The expression of miR-19a-3p was downregulated significantly in the mouse leukemia macrophage cell line RAW264.7 after culturing with mouse breast cancer cell line 4T1-conditioned medium of three candidates (miR-19a-3p, miR-29a and miR-503) and was compared with that in wild-type RAW264.7 cells (Figure 1a and b) . As miR-19a-3p is broadly conserved among vertebrates, an investigation was conducted to determine whether its functions are similar to that of human macrophage cells. This was done by detecting the expression of miR-19a-3p in the human monocyte/ macrophage cell line U937 cocultured with human breast cancer cell line MDA-MB-231-conditioned medium; the results were similar to those obtained in Figure 1c . To investigate the miRNA expression patterns in TAMs in vivo that were induced by TME, total RNA was collected from TAMs derived from mouse 4T1 breast cancer tissue, and the miRNA profile was determined using the miRNA qPCR technique. The data indicate that miR-19a-3p expression was significantly decreased in TAMs compared with that in normal macrophages from the spleen (Figure 1d ). Simultaneously, we confirmed the expression of Fra-1 in RAW264.7 cells cocultured with 4T1-conditioned medium. The data reveal an upregulated Fra-1 gene expression (Figure 1e ). The same phenomenon was observed in the human macrophage U937 cell line (Figure 1f ). Taken together, these results suggest that the 3 0 UTR of the Fra-1 gene is a potential target of miR-19a-3p that can regulate Fra-1 gene expression in TAMs within breast tumor TME.
MiR-19a-3p downregulates Fra-1 and its downstream pathway genes The regulation of miRNA to the transcription factor and its governing downstream signaling pathway has been recognized to be critical for malignant tumor progress. Here, the opposite of the relationship between Fra-1 and miR-19a-3p expression of TAMs was observed, implying that the 3 0 UTR of Fra-1 could be a potential target of miR-19a-3p. To confirm this, the miR-19a-3p mimic was synthesized and transfected into RAW264.7 cells. In this case, Fra-1 expression was significantly suppressed by the miR19a-3p mimic within 24 h (Figure 2a and Supplementary Figure 1B) , but not by miR-503 and miR-29a (Supplementary Figure 1A) . The same result was also observed in primary mouse macrophages and human macrophage U937 cells (Figure 2b) . Further, to confirm our prediction, we generated a reporter vector consisting of the luciferase coding sequence followed by the 3 0 -UTR of the Fra-1(Luc-Fra-1-3 0 -UTR) mutant, with the putative binding site used as a negative control (Figure 2c ). These constructs were co-transfected into RAW264.7 cells, and luciferase activity was analyzed. These co-transfection experiments showed that miR-19a-3p decreased the luciferase activity of Luc-Fra-1-3 0 -UTR, but had only a minimal effect with the negative control plasmid (Figure 2d ). To further explore whether miR-19a-3p could regulate the downstream STAT3 pathway of Fra-1 via inhibition of Fra-1 expression, the miR-19a-3p mimic and inhibitor were synthesized and then transfected into RAW264.7 cells. In this case, the expressions of pSTAT3 and STAT3 and of their target gene VEGF-A were either suppressed (Figure 2e ) or promoted ( Figure 2f ). Data from immunofluorescence experiments reveal the same trend ( Figure 2g ). Together, these findings indicate that miR19a-3p can bind to the 3 0 -UTR of Fra-1 and regulate the expression of Fra-1 and the activity of its downstream pathway. Dualluciferase signal reporter array showed that miR-19a-3p also downregulates other signaling pathways that promote M2 polarization of macrophages, especially the glucocorticoid and NFAT pathway, and upregulates the estrogen pathway that inhibits the M2 polarization of TAMs (Supplementary Figure 1c) . Downregulated miR-19a-3p promotes the M2 phenotype of TAMs by releasing control of Fra-1/STAT3 pathway activity Our previous study indicated that overexpression of Fra-1 in TAMs promotes the invasion and progression of breast cancer cells. 19 We determined whether inhibition of Fra-1 by miR-19a-3p in RAW264.7 cells could indeed impair the invasion and migration capacity of breast tumor cells in the TME. To this end, three mouse breast tumor cell lines, 4T1, 4T07 and EMT6, were used as follows. Transwell assays indicated that the invasion capacity of these three tumor cell lines was significantly suppressed when cocultured with RAW264.7 cells after being transfected with miR-19a-3p ( Figure 3a) . Meanwhile, the wound healing experiment clearly showed that the migration property of 4T1 and EMT6, except 4T07, was also attenuated (Figure 3b ), indicating that transfection of miR-19a-3p into TAMs inhibits any effect that it may have on the metastatic properties of breast tumor cells.
Polarization of M1 to the M2 phenotype is an important transformation of macrophages in the TME. To prove that the regulation of miR-19a-3p may support the maintenance of the M2 phenotype of TAMs in the breast tumor TME, an analysis of M1 or M2 marker expression was performed in mouse primary macrophages or RAW264.7 cells transfected with either the miR-19a-3p mimic or its miR-negative control using real-time PCR or flow cytometry. Results from these experiments showed that the expression of M2 markers Arg1 and CD206 was significantly decreased. Thus, reverse M1 marker Mcp1 and Nos2 expressions were increased in macrophages that were transfected with the miR-19a-3p mimic when compared with negative controls (Figures  4a and b) . Further, experiments were designed to test whether cytokines secreted by macrophages could be changed by overexpressing miR-19a-3p in RAW264.7 cells. To this end, supernatants were collected from RAW264.7 cells transfected with either the miR-19a-3p mimic or its miR-negative control and used to detect cytokine levels by means of a mouse cytokine array panel. In fact, M2-type cytokines such as interleukin (IL)-4, IL-6, IL-10 and IL-13 were significantly decreased, whereas M1-type cytokines CXCL10 and Mcp1 were increased, when miR-19a-3p was overexpressed in RAW264.7 cells (Figure 4c ). These observations suggest that miR-19a-3p can help transform the M2 phenotype into RAW264.7 cells by regulating the expression of the Fra-1/STAT3 pathway.
MiR-19a-3p inhibits metastasis of 4T1 breast cancer cells by suppressing M2 macrophage function in vivo After identifying the function of miR-19a-3p in transforming the M2-M1 phenotype of TAMs in vitro, we explored its function in vivo, particularly as it aids in the invasion and migration of breast cancer cells. For this purpose, 4T1-luciferase-labeled cells were injected into Balb/c mice. Thereafter, these mice xenografted with 4T1 cells were injected twice a week intratumorally with miR19a-3p agomir, a chemically modified miRNA mimic, or with the negative control. Tumor mass and lungs from these mice were harvested after 3 weeks (Figure 5a ) and further tested for the presence of CD206-positive cells by immunohistochemistry and immunofluorescence staining. The number of CD206-positive cells in tumor tissue was seen to be significantly decreased after injection with miR-19a-3p agomir (Figures 5b and c) . Consistent with these results obtained by immunohistochemical staining, a decrease was observed in the number of F4/80 þ CD206 þ cells in tumors injected with miR-19a-3p agomir compared with negative controls, as found by flow cytometry (Figure 5d ).
To determine whether miR-19a-3p inhibited the growth and metastasis of 4T1 breast tumor by suppressing macrophages with the M2 phenotype, the tumor volume and lung metastasis in Balb/c mice were ascertained by live image and hematoxylin and eosin staining. We found that injecting miR-19a-3p agomir into the 4T1 tumor model resulted in a significantly attenuated metastatic capacity for tumor cells, but not for original tumor growth (Figures 5e and f) . These data suggest that miR-19a-3p mainly regulates TAMs to inhibit metastases of 4T1 tumor cells. Together, our data indicate that miR-19a-3p is downregulated in macrophages with the M2 phenotype. The low expression of miR-19a-3p apparently has an important role in the upregulation of Fra-1 expression and induction in M2 macrophage polarization, which may contribute considerably to facilitating the metastasis and progression of breast cancer.
IL-6 activates the M2 polarization-related signal pathway by inhibiting miR-19a-3p expression of TAMs IL-6 has been reported to be a regulator in the promotion of M2 macrophages. To better understand whether IL-6 in the TME is involved in the downregulation of miR-19a-3p in TAMs, an effort was made to detect miR-19a-3p expression by real-time PCR with IL-6. The results showed that miR-19a-3p was indeed inhibited after 6 h of stimulation. Meanwhile, we also found that the mRNA of Fra-1 expression was also promoted by TAMs cultured in medium mixed with IL-6 (Figure 6a ). Combined with these results obtained previously, here we drew out a schema summarizing the mechanism by which TME regulates the phenotype of TAMs by suppressing miR-19a-3p expression. We found that, specifically, IL-6 produced by tumor cells inhibits miR-19a-3p expression of TAMs; subsequently, signal pathways such as AP1/STAT3, glucocorticoid and nuclear factor of activated T cells (NFAT) are activated; and TAMs are polarized to the M2 phenotype to promote the progression and metastasis of tumor cells (Figure 6b ).
DISCUSSION
In contrast to normal macrophages, there is increasing evidence that tumor-associated macrophages are capable of recruiting to the tumor site, increasing tumor angiogenesis and tumor cell However, the molecular mechanisms that initiate this transformation of TAMs are still unclear. MicroRNAs are a group of small RNAs that regulate gene expression, some of which have also been reported to be oncogenes involved in tumorigenesis. Recently, certain miRNAs have been discovered that are involved in the progression of monocyte-macrophage differentiation into osteoclasts. [23] [24] [25] Nevertheless, a few studies have been conducted to investigate the role of miRNAs that control the phenotype transformation of TAMs.
To date, numerous miRNA profiling methods, such as real-time PCR, bead-based flow-cytometric profiling technology and microarray, have been identified for the diagnosis, staging, progression, However, the profiling signatures of different subpopulations of macrophages have been rarely studied. In this investigation, we combined real-time PCR and bioinformatics to explore the miRNA profiling of TAMs in both mouse and human cell lines. It was found that miRNAs such as miR-19a-3p, miR-29a and miR-503 show significant downregulation in TAMs compared with normal macrophages. It has been widely reported that miRNAs inhibit gene expression by binding to the 3 0 UTR region of genes and thereby degrade the mRNA or block translation. 25, [27] [28] [29] Here we demonstrated that only miR-19a-3p, and not miR-29a or miR-503, inhibits the expression of the Fra-1 gene in TAMs. A number of studies reported that infiltration of macrophages into tumor loci correlated with poor prognosis for multiple cancer types. [30] [31] [32] Fra-1 was also reported to be a key transcription factor during the progression of transformation of TAMs. In our previous study, Fra-1 was found to act as a proto-oncogene in initiating the activation of the IL-6/JAK/STAT3 signaling pathway. Thereby, a malignant switch was created in breast tumor cells, leading to the increased release of proangiogenic factors, including matrix metallopeptidase 9 (MMP-9), VEGF and transforming growth factor beta (TGF-b), from tumor cells. This also included the intensified invasion and progression of breast cancer. 19 On the other hand, the results of this study showed that miR-19a-3p also inhibits other signaling pathways that promote M2 polarization of macrophages, especially the glucocorticoid pathway, which promotes macrophage recruitment and M2 macrophage activation by activating the STAT3 pathway 33 and the NFAT pathway, which leads to increased production of M2 cytokines such as IL-4 and IL-6 in Th2 cells. 34 Meanwhile, the estrogen pathway was reported to inhibit the alternative activation of TAMs. 32 Moreover, decreased levels of M2 cytokines secreted by TAMs were also observed. Significantly, when miR-19a-3p was overexpressed in TAMs, the facilitated capacity of the migration and invasion of breast cancer cells was attenuated to varying degrees. In this regard, it was reported that migration and invasion of colon tumor cells could be inhibited via silencing of Fra-1, 35-37 These results revealed that miR-19a-3p has an important role in inhibiting M2 macrophage polarization by regulating M2 polarization-related signaling pathways.
There exists abundant evidence to suggest that the proportion of TAMs within the tumor mass is correlated with the metastatic potential of the tumor. In fact, by remodeling the tumor microenvironment and relaxing the extracellular matrix of tumor cells, TAMs allow tumor cells to detach from the tumor mass and disseminate, resulting in distant metastasis. Here, in the Balb/c mouse model, we found that intratumoral injection of miR-19a-3p not only decreased the population of TAMs but also inhibited lung metastasis of 4T1 breast cancer cells. In addition, IL-6 was found to act as a negative regulator of miR-19a-3p in the tumor microenvironment. Although the detailed mechanism of IL-6 regulating miR-19a-3p remains to be explored, data reported here make it clear that the tumor microenvironment promotes the M2 phenotype of TAMs by inducing an miRNA profile that inhibits miR-19a-3p expression in order to activate the signal pathways that promote M2 polarization of TAMs.
In summary, the findings reported here support the hypothesis that miR-19a-3p, which regulates TAMs in the breast tumor in TAMs is likely due to TME induction, which promotes transformation of M1 to M2 and results in the enhancement of migration and invasion of breast cancer cells (Figure 6b ). Therefore, it is possible that miR-19a-3p could also become a potentially useful therapeutic target for the treatment of breast cancer. In this regard, chemical modifications, some of which have already been developed for siRNAs, can be applied to miRNAs. 38 In addition, nanoparticle-mediated delivery of synthetic miRNAs, specifically to tumor-associated leukocytes, has been reported as an efficient strategy to re-program the immunological control of metastatic cancers. 39 
MATERIALS AND METHODS

Animals and cell lines
Female Balb/c mice, 6-8 weeks of age, were purchased from the Chinese Academy of Medical Sciences Institute of experimental animals. All experiments involving animals were performed according to the guidelines on laboratory animals of Nankai University and were approved by the Institute Research Ethics Committee at the Nankai University (Permit number: 10011). Mouse breast cancer cell lines 4T1 and 4T07 and the mouse leukemic macrophage cell line RAW264.7 were obtained from Dr R A Reisfeld (The Scripps Institute, La Jolla, CA, USA). The human macrophage cell line U937 and mouse breast cancer cell line EMT6 were purchased from the Fourth Military Medical University (Xi 0 an, China). The 4T1, U937 and RAW264.7 cell lines were cultured in 1640 medium supplemented with antibiotics (100 U/ml penicillin-0.1 mg/ml streptomycin) and 10% fetal bovine serum (FBS). Cell line 4T07 was cultured in 1640 medium with antibiotics (100 U/ml penicillin-0.1 mg/ml streptomycin) to a final concentration containing 2 mM glutamine, 1% sodium pyruvate bicarbonate, 1% HEPES and 10% FBS.
Prediction of miRNAs by real-time PCR
The miRNAs regulating the expression of Fra-1 were predicted with the web software TargetScan (http://www.targetscan.org/). Small RNA of RAW264.7 and CD11b þ cells was purified and enriched with the miRcute miRNA Isolation Kit (Tiangen, Beijing, China). MiRNAs were prolonged by Escherichia coli poly(A) polymerase, and reverse transcription was performed with the miRcute miRNA First-Strand cDNA Synthesis Kit and real-time PCR with the miRcute miRNA qPCR detection kit (Tiangen). Forward primers were designed on the basis of the mature sequences of mouse miR-19a-3p, miR-503 and miR-29a, and the reverse primer was provided by the miRNA real-time PCR kit (Tiangen). The forward primer sequences are as follows: miR-19a-3p: 5 0 -CGCTGTGCAAATCTATGCAAAACT-GAAA-3 0 , miR-29a: 5 0 -CGCTAGCACCATCTGAAATCGGTTAAA-3 0 , miR-503: 5 0 -TAGCAGCGGGAACAGTACTGCAG-3 0 . The universal reverse primer was provided in the miRcute miRNA qPCR detection kit.
Total RNA of raw cells was isolated with TRIzol reagent (Invitrogen, Grand Island, NY, USA). Reverse transcription was performed using TransScript First-Strand cDNA Synthesis Supermix, and real-time PCR was performed with TransScript top green qPCR supermix (TransGen, Beijing, China) in triplicate.
Western blotting
Total protein from RAW264.7 cells and U937 cells was scraped from the culture plates after 24 and 48 h. Thereafter, the miRNA mimic or inhibitor was transfected into the cells and lysed in RIPA lysate buffer, and the cell lysate was incubated on ice for 30 min and centrifuged at 13 000 rpm for 10 min before the supernatant was collected. Western blotting was performed by using polyclonal primary rabbit anti-murine antibodies Fra-1 and VEGF and mouse anti-murine antibodies STAT3 or pSTAT3, and b-actin antibody as the loading control (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Flow cytometry assays
Flow cytometry was used for the detection of cytomembrane expression of F4/80 and CD206. Macrophages transfected with either miR-19a-3p mimic or miR-negative control mimic (Ribo Biotech, Guangzhou, China) were assayed according to the instructions provided by the manufacturer (BD Bioscience, San Jose, CA, USA). Briefly, macrophages were harvested after transfection and then stained with the F4/80 antibody conjugated with PE (BD Biosciences) and with the CD206 antibody conjugated with FITC (BD Biosciences), followed by dual-color flow cytometry analysis with a BD Biosciences Digital LSR II. Data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA).
Dual-luciferase report system assays The 3 0 UTR of Fra-1 was cloned to the psiCHECK2 vector (Promega, Madison, WI, USA). To generate the Fra-1 mutant reporter, the seed region of the Fra-1 3 0 UTR was mutated to remove all complementarity to nucleotides 1-8 of miR-19a-3p. HEK293T cells were co-transfected with 300 ng of firefly luciferase reporter vector and 50 nmol miR-19a-3p or miRnegative control using Lipofectamine 2000 (Invitrogen) in 24-well plates. Luciferase assays were performed 24 h after transfection, using the dualluciferase reporter assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity and detected using the GloMaxMulti detection system (Promega).
Signal pathway assays
Signal pathway assays were performed according to the protocol provided by the Cignal Finder Reporter Array kit (Qiagen, Germantown, MD, USA). The miR-19a-3p and miR-NC mimics were co-transfected with reporter into HEK293T cells to a final concentration of 100 nM. Luciferase activity was determined 60 h after transfection. Cytokine secreting and stimulating assays The RAW264.7 macrophage cell-conditioned medium was collected 24 h after the transfection of miRNA mimics. Cytokines secreted by RAW264.7 cells, either transfected with miR-19a-3p mimic or miR-negative control, were detected by the Mouse Cytokine Array Panel A (R&D, Minneapolis, MN, USA) based on the Proteome Profiler Array Protocol. Cytokine array data on the developed X-ray film were quantitated by scanning the film on a transmission-mode scanner and analyzing the array image file using ImageJ software (http//:rsbweb.nih.gov/ij/).
To detect the miR-19a-3p regulator in the TME, RAW264.7 cells were cultured in complete RPMI-1640 medium mixed with mouse IL-6 (Cell Signaling Technology, Danvers, MA, USA) at a final concentration of 10 ng/ ml or without mouse IL-6 as a negative control for 6 h before RNA extraction.
Cell invasion and migration assay
Transwell chambers (Costar, Cambridge, MA, USA) with 5-mm-pore polycarbonate filters were used to assess the invasion properties of tumor cells. Cells 4T1, 4T07 and EMT6 were seeded (1 Â 10 5 cells/chamber) on top of the cylindrical chambers in the presence of RPMI-1640 medium with 1% FBS, whereas RAW264.7 cells (1 Â 10 5 cells/well) were seeded in the cells below in RPMI-1640 medium plus 10% FBS. Cell invasion was observed 24 h after culturing at 37 1C in 5% CO 2 , and after 12 h for EMT6 cells. Noninvasive cells were removed from the bottom of the chambers using cotton swabs. Invasive cells on the other surfaces of the membrane were fixed in absolute methanol and stained with 0.1% crystal violet (Invitrogen) for 5 min at room temperature and subjected to microscopic study. Cell migration was assessed by wound healing experiments. Tumor cells (4 Â 10 5 cells/well) were seeded in 12 orifice plates in 50% RPMI-1640 medium with 1% FBS plus 50% RAW264.7 cell-conditioned medium. After 24 h the bottom of the wells were scraped using 1 ml Pipette Tips. The widths of the wound were recorded after 24 h under a microscope. The wound healing rate was quantified by detecting the percentage of width of the closed wound versus that of the original wound.
Immunohistochemistry and immunofluorescence
For immunohistochemical staining analysis, 4T1 tumor tissue paraffin sections were fixed and stained with the Rabbit immunoCruz staining system (Santa Cruz Biotechnology) using rabbit anti-murine CD206 mAbs. Horseradish peroxidase-conjugated goat anti-mouse secondary Ab was used and slides were mounted with the cells to be visualized microscopically. For immunofluorescence, rat anti-murine CD206 mAb was used for staining of 4T1 tumor tissue frozen sections. Rabbit anti-murine Fra-1, VEGF, and mouse anti-murine Stat-3, pSTAT3, mAb were used for staining of RAW264.7 cells.
Animal experiments
The 4T1-luciferase breast cancer cells (5 Â 10 4 ) were injected subcutaneously into the second mammary fat pad of each female Balb/c mouse. The miR-19a-3p agomir (chemically modified miRNA mimics) and negative control were injected intratumorally twice a week and 7 days later for 3 weeks. Luciferase activity was detected every 7 days for 3 weeks. On day 28, the tumor of each mouse was harvested for flow cytometry, immunofluorescence and immunohistochemical analyses.
Statistical analysis
Values were expressed as means ± s.e.m. Significance was determined using the Student's t-test. A value of Po0.05 was used as the criterion for statistical significance. *Indicates significant difference with Po0.05; **indicates significant difference with Po0.01; ***indicates significant difference with Po0.001.
